AU2001246916B2 - Oxadiazole derivatives having anticancer effects - Google Patents

Oxadiazole derivatives having anticancer effects Download PDF

Info

Publication number
AU2001246916B2
AU2001246916B2 AU2001246916A AU2001246916A AU2001246916B2 AU 2001246916 B2 AU2001246916 B2 AU 2001246916B2 AU 2001246916 A AU2001246916 A AU 2001246916A AU 2001246916 A AU2001246916 A AU 2001246916A AU 2001246916 B2 AU2001246916 B2 AU 2001246916B2
Authority
AU
Australia
Prior art keywords
compound
optionally substituted
examples
dmso
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001246916A
Other languages
English (en)
Other versions
AU2001246916A1 (en
Inventor
Ryuji Maekawa
Fumihiko Watanabe
Takayuki Yoshioka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU2001246916A1 publication Critical patent/AU2001246916A1/en
Application granted granted Critical
Publication of AU2001246916B2 publication Critical patent/AU2001246916B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2001246916A 2000-04-21 2001-04-16 Oxadiazole derivatives having anticancer effects Ceased AU2001246916B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000120234 2000-04-21
JP2000-120234 2000-04-21
PCT/JP2001/003214 WO2001083463A1 (fr) 2000-04-21 2001-04-16 Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaires

Publications (2)

Publication Number Publication Date
AU2001246916A1 AU2001246916A1 (en) 2002-01-31
AU2001246916B2 true AU2001246916B2 (en) 2004-10-07

Family

ID=18631080

Family Applications (2)

Application Number Title Priority Date Filing Date
AU4691601A Pending AU4691601A (en) 2000-04-21 2001-04-16 Oxadiazole derivatives having anticancer effects
AU2001246916A Ceased AU2001246916B2 (en) 2000-04-21 2001-04-16 Oxadiazole derivatives having anticancer effects

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU4691601A Pending AU4691601A (en) 2000-04-21 2001-04-16 Oxadiazole derivatives having anticancer effects

Country Status (16)

Country Link
US (2) US6720343B2 (US07585860-20090908-C00150.png)
EP (1) EP1277744A4 (US07585860-20090908-C00150.png)
JP (1) JP3974781B2 (US07585860-20090908-C00150.png)
KR (1) KR100542780B1 (US07585860-20090908-C00150.png)
CN (1) CN1199956C (US07585860-20090908-C00150.png)
AU (2) AU4691601A (US07585860-20090908-C00150.png)
BR (1) BR0110211A (US07585860-20090908-C00150.png)
CA (1) CA2406685C (US07585860-20090908-C00150.png)
HU (1) HUP0300619A3 (US07585860-20090908-C00150.png)
MX (1) MXPA02010325A (US07585860-20090908-C00150.png)
NO (1) NO324868B1 (US07585860-20090908-C00150.png)
PL (1) PL203161B1 (US07585860-20090908-C00150.png)
RU (1) RU2275371C2 (US07585860-20090908-C00150.png)
TW (1) TWI294877B (US07585860-20090908-C00150.png)
WO (1) WO2001083463A1 (US07585860-20090908-C00150.png)
ZA (1) ZA200208307B (US07585860-20090908-C00150.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
WO2005012268A1 (ja) * 2003-07-30 2005-02-10 Shionogi & Co., Ltd. イソオキサゾール環を有するスルホンアミド誘導体
AU2005299851B2 (en) * 2004-10-22 2011-03-17 Merck Sharp & Dohme Corp. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
MEP43308A (en) * 2006-05-09 2011-02-10 Pfizer Prod Inc Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
KR100783585B1 (ko) 2006-08-22 2007-12-07 한국생명공학연구원 스탯의 활성을 저해하는 옥사다이아졸 우레아 화합물을 유효성분으로 함유하는 암의 예방 또는 치료제
CN104072489B (zh) 2007-08-27 2017-07-07 达特神经科学(开曼)有限公司 治疗用异噁唑化合物
TW200930363A (en) * 2007-12-10 2009-07-16 Actelion Pharmaceuticals Ltd Novel thiophene derivatives
AR077969A1 (es) 2009-08-31 2011-10-05 Abbott Healthcare Products Bv Derivados de (tio)morfolina comomoduladores de s1p
TWI522361B (zh) 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
TW201206893A (en) 2010-07-09 2012-02-16 Abbott Healthcare Products Bv Bisaryl (thio) morpholine derivatives as S1P modulators
TWI543984B (zh) 2010-07-09 2016-08-01 艾伯維公司 作為s1p調節劑的螺-哌啶衍生物
CN103450167A (zh) * 2012-05-28 2013-12-18 南京大学 一类含1,3,4-噁二唑和吡嗪环的酰腙类衍生物及其制备方法与用途
US10710994B2 (en) * 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
KR20220123634A (ko) 2019-10-31 2022-09-08 이스케이프 바이오, 인크. S1p-수용체 조절제의 고체 형태
CN113264899B (zh) * 2021-04-09 2022-06-14 台州学院 一种1，3，5-噁二嗪类化合物及其制备和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004780A1 (fr) * 1997-07-22 1999-02-04 Shionogi & Co., Ltd. Agent therapeutique ou prophylactique de traitement de la glomerulopathie
WO2000015213A1 (fr) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Agent de prevention ou de traitement de l'insuffisance cardiaque congestive

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004780A1 (fr) * 1997-07-22 1999-02-04 Shionogi & Co., Ltd. Agent therapeutique ou prophylactique de traitement de la glomerulopathie
WO2000015213A1 (fr) * 1998-09-11 2000-03-23 Shionogi & Co., Ltd. Agent de prevention ou de traitement de l'insuffisance cardiaque congestive

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Chem.Rev.(1999)99, 2735-76 *

Also Published As

Publication number Publication date
JP3974781B2 (ja) 2007-09-12
US20030203940A1 (en) 2003-10-30
RU2275371C2 (ru) 2006-04-27
PL359415A1 (en) 2004-08-23
HUP0300619A2 (hu) 2003-07-28
WO2001083463A1 (fr) 2001-11-08
MXPA02010325A (es) 2003-04-25
NO20025035L (no) 2002-12-19
EP1277744A1 (en) 2003-01-22
PL203161B1 (pl) 2009-08-31
BR0110211A (pt) 2003-06-03
CN1199956C (zh) 2005-05-04
KR100542780B1 (ko) 2006-01-11
US20040122066A1 (en) 2004-06-24
KR20030019357A (ko) 2003-03-06
CA2406685C (en) 2006-10-31
US6720343B2 (en) 2004-04-13
AU4691601A (en) 2001-11-12
CN1436179A (zh) 2003-08-13
NO20025035D0 (no) 2002-10-18
NO324868B1 (no) 2007-12-17
EP1277744A4 (en) 2007-07-11
ZA200208307B (en) 2003-10-15
HUP0300619A3 (en) 2006-02-28
CA2406685A1 (en) 2002-10-17
TWI294877B (US07585860-20090908-C00150.png) 2008-03-21

Similar Documents

Publication Publication Date Title
AU2001246916B2 (en) Oxadiazole derivatives having anticancer effects
US6897237B2 (en) MMP-12 inhibitors
CA2701053C (en) Oxadiazole- and oxazole-substituted benzimidazole- and indole-derivatives as dgat1 inhibitors
US6420367B1 (en) Pyrimidine derivatives exhibiting antitumor activity
CN101605777A (zh) 作为醛固酮合酶抑制剂的咪唑类化合物
TW200900397A (en) Tricyclic compounds as matrix metalloproteinase inhibitors
KR20010113820A (ko) 옥사디아졸 고리를 갖는 술폰아미드 유도체
US6949566B2 (en) Thiazole and oxazole derivatives
EP1491190A1 (en) Decomposition inhibitor for extracellular matrix of cartilage
EP1666469A1 (en) Plasminogen activator inhibitor-1 inhibitor
JP4219810B2 (ja) Ｍｍｐ阻害作用を有するスルホンアミド誘導体
EP1491520A1 (en) Process for production of bisphenol a
JP7449300B2 (ja) ファルネソイドｘ受容体モジュレータとして有用な置換アミド化合物
CN108383828A (zh) 作为趋化因子受体调节剂的新的1，2-双-磺酰胺衍生物
CA3162388A1 (en) 4-phenyl-n-(phenyl)thiazol-2-amine derivatives and related compounds as aryl hydrocarbon receptor (ahr) agonists for the treatment of e.g. angiogenesis implicated or inflammatory disorder
US7825146B2 (en) Sulfonamide derivative having isoxazole ring

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired